SOPHiA GENETICS (NASDAQ:SOPH) vs. OptimizeRx (NASDAQ:OPRX) Financial Comparison

SOPHiA GENETICS (NASDAQ:SOPH) and OptimizeRx (NASDAQ:OPRX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, dividends, earnings and risk.

Institutional & Insider Ownership

31.6% of SOPHiA GENETICS shares are held by institutional investors. Comparatively, 76.5% of OptimizeRx shares are held by institutional investors. 4.9% of SOPHiA GENETICS shares are held by insiders. Comparatively, 7.5% of OptimizeRx shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares SOPHiA GENETICS and OptimizeRx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
SOPHiA GENETICS	-93.86%	-132.47%	-45.97%
OptimizeRx	4.66%	9.44%	7.11%

Risk and Volatility

SOPHiA GENETICS has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500. Comparatively, OptimizeRx has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for SOPHiA GENETICS and OptimizeRx, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SOPHiA GENETICS	1	1	3	0	2.40
OptimizeRx	1	2	6	0	2.56

SOPHiA GENETICS currently has a consensus price target of $10.00, indicating a potential upside of 21.95%. OptimizeRx has a consensus price target of $11.57, indicating a potential upside of 32.70%. Given OptimizeRx’s stronger consensus rating and higher probable upside, analysts clearly believe OptimizeRx is more favorable than SOPHiA GENETICS.

Earnings and Valuation

This table compares SOPHiA GENETICS and OptimizeRx”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SOPHiA GENETICS	$77.27 million	8.90	-$79.00 million	($1.15)	-7.13
OptimizeRx	$98.65 million	1.66	$5.13 million	$0.23	37.91

OptimizeRx has higher revenue and earnings than SOPHiA GENETICS. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than OptimizeRx, indicating that it is currently the more affordable of the two stocks.

Summary

OptimizeRx beats SOPHiA GENETICS on 13 of the 14 factors compared between the two stocks.

About SOPHiA GENETICS

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events. The company was founded in 2006 and is based in Waltham, Massachusetts.